Clinical analysis on diagnostic accuracy of Bosch Vivalytic SARS-CoV-2 point-of-care test and evaluation of cycle threshold at admission for COVID-19 risk assessment

Table 1 Patients baseline characteristics at admission

Variable	COVID-19 n = 46		Non-COVID-19 n = 74		P-value
Age (years)	55.5	38.5–65.75	63.05	± 17.41	0.006^a
Sex (female)	15	(33.3%)	39	(52.7%)	0.057^a
C-reactive protein (mg/dl)	5.96	(± 5.348)	0.4	(0.4–2.7)	< 0.001^b
Hemoglobine /g/dl)	13.46	(± 2.068)	12.79	(± 2.164)	0.094^b
Leukocytes (K/μl)	6.75	(4.575–9.85)	7.9	(6.15–10.2)	0.169^b
Platlets (K/μl)	217.5	(179–261.8)	258.5	(195.3–310.3)	0.116^b
Lactate dehydrogenase (U/I)	362.3	(± 136.1)	236	203.3–301	0.014^b
Aspartate Aminotransferase (U/I)	38	(26.5–55)	24	17–31.25	0.614^b
CAD*	8	(17.4%)	15	(20.3%)	0.495^c
Hypertension	18	(39.1%)	36	(48.6%)	0.349^c
Pulmonary disease	9	(19.5%)	25	(33.9%)	0.101^c
Length of Stay (days)	9.5	(4.75–15.25)

*CAD = Coronary Artery Disease; Continuous variables are presented as mean ± standard deviation (SD) if found to follow a Gaussian distribution according to the D’Agosstino-Pearson omnibus normality test or as median ± lower and upper quartiles if found to follow a non-Gaussian distribution.; ^aNonparametric Mann–Whitney U test to compare ranks; ^bUnpaired t-test; ^cFisher’s exact test

ISSN: 1471-2334